

CURRICULUM VITAE

DAVID G. MILLER, MD

OFFICE ADDRESSES Retina Associates of Cleveland, Inc.
690 White Pond Drive, Suite 120; Akron, Ohio 44320
24075 Commerce Park; Cleveland, Ohio 44122
4690 Munson Street NW; Canton, Ohio 44718
650 Graham Road, Suite 103/104; Cuyahoga Falls, Ohio 44221
340 Oxford Street, Suite 210; Dover, Ohio 44622
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052
3591 Reserve Commons Drive; Medina, Ohio 44256
9485 Mentor Avenue, Suite 110; Mentor, Ohio 44060
15299 Bagley Road, Suite 200; Cleveland, Ohio 44130
17534 Royalton Road, Suite 201; Strongsville, Ohio 44136
170 North Road NE; Warren, Ohio 44483
4350 Crocker Road, Suite 200; Westlake, Ohio 44145
5390 Belmont Avenue; Youngstown, Ohio 44505

TELEPHONE 216-831-5700

WEBSITE www.retina-doctors.com

PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 1998–

Practice limited to retinal diseases and surgery

President, 2009–

Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD;
Scott D. Pendergast, MD; Joseph M. Coney, MD; Jerome P. Schartman, MD; Llewelyn J.
Rao, MD; Arnold F. Nothnagel, DO; Shawn A. Lewis, MD; Sean M. Platt, MD; Matthew K.
Adams, MD, MBA; Hang Pham, MD

Cleveland Eye and Laser Surgery Center

Founder

Medical Director, 2007–

President of Governing Board, 2007–

EDUCATION/TRAINING

Fellowship

Vitreoretinal Surgery and Disease Fellowship
Massachusetts Eye and Ear Infirmary
Harvard Medical School – Clinical Instructor
Boston, Massachusetts
1997–1998

<i>Residency</i>	Ophthalmology Indiana University Medical Center Indianapolis, Indiana 1994–1997 Chief Resident, 1996–1997
<i>Internship</i>	Internal Medicine University Hospital Cincinnati, Ohio 1993–1994
<i>Medical School</i>	University of Cincinnati Cincinnati, Ohio 1989–1993, MD Alpha Omega Alpha Medical Honor Society, junior year inductee Medical Student Research Award College of Medicine Merit Award James R. Nicholl Memorial Scholar
<i>College</i>	Ohio State University Columbus, Ohio 1985–1989, BS (Chemistry) Summa cum laude with Honors in the Liberal Arts Outstanding Senior in Chemistry Award Phi Beta Kappa Ohio Regents Scholar Ohio State University Distinguished Scholar President’s Award for Excellence in Scholarship

LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio

Diplomate, American Board of Ophthalmology, 1999; recertified for 2009-2019

ACADEMIC AND TEACHING ACTIVITIES

Surgical Eye Expeditions (SEE) International (nonprofit to third-world ophthalmic surgery instruction)

Volunteer Faculty, 2016–

ORBIS International (nonprofit organization devoted to blindness prevention and treatment in developing countries)

Volunteer Faculty, 2013–

International Consultant, CyberSight Telemedicine Program (web-based telemedicine initiative for training, education, and clinical support), 2013–

Ohio Eye Injury Registry
Chairman, 2002–

Chief Teaching Resident, Indiana University Medical Center, Department of Ophthalmology;
1996–1997

Medical student lectures and testing, grand rounds scheduling, guest speakers,
interdepartmental education

Medical Biochemistry Recitation Leader, University of Cincinnati; 1990–1991
Biochemical problem-solving guidance for first-year medical students

Research Intern, National Institutes of Health, Bethesda, Maryland; 1989
Biochemical studies concerning ozone oxidation of proteins

HONORS AND AWARDS

Charter Member, Retina Hall of Fame, 2017

America's Most Honored Professionals Award, 2017

Best Doctors in America, 2011-2019

Patients' Choice Award, 2014, 2016

PROFESSIONAL SOCIETIES AND COMMITTEES

Cleveland Ophthalmological Society
President, 2004–2005
President-elect, 2003–2004
Vice President, 2002–2003
Treasurer, 2000–2002

Diabetic Retinopathy Clinical Research Network Group
Protocol Development Committee, 2005

Scientific reviewer, *Survey of Ophthalmology*

Scientific reviewer, *Journal of Cataract and Refractive Surgery*

Scientific reviewer, *Retina, The Journal of Retinal and Vitreous Diseases*

MEMBERSHIPS

Member, Phi Beta Kappa
Alpha Omega Alpha Medical Honor Society
American Academy of Ophthalmology
American Eye Study Club
American Medical Association

American Society of Retinal Specialists (formerly the Vitreous Society)
Association for Research in Vision and Ophthalmology
Massachusetts Eye and Ear Infirmary Alumni Association
Ohio State Medical Association
Ohio Ophthalmological Society
Phi Beta Kappa

HOSPITAL & ASC AFFILIATIONS

Cleveland Eye and Laser Surgery Center; Cleveland, Ohio
Brainard Surgery Center; Cleveland, Ohio
Cleveland Clinic Health System; Cleveland, Ohio
Summa Health; Akron, Ohio

RESEARCH ACTIVITIES

NIH-funded Grants

DRCRnet Protocol V. Treatment for central involved diabetic macular edema in eyes with very good visual acuity

Principal Investigator, 2014–2018

DRCRnet (Diabetic Retinopathy Clinical Research Network) Protocol T. A comparative effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab for diabetic macular edema

Principal investigator, 2012–2015

DRCRnet Protocol K. Course of response to focal photocoagulation for diabetic macular edema

Principal investigator, 2007–2008

DRCRnet Protocol D. Evaluation of vitrectomy for diabetic macular edema

Principal investigator, 2006–2012

DRCRnet Protocol I. Intravitreal ranibizumab or triamcinolone acetonide in combination with laser photocoagulation for diabetic macular edema

Principal investigator, 2007–2014

DRCRnet Protocol AB. Intravitreal anti-VEGF vs. prompt vitrectomy for vitreous hemorrhage from proliferative diabetic retinopathy

Co-investigator, 2017–

DRCRnet Protocol W. Intravitreal anti-vascular endothelial growth factor treatment for prevention of vision threatening diabetic retinopathy in eyes at high risk

Co-investigator, 2017–

DRCRnet Protocol U. Short-term evaluation of combination corticosteroid+anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes

Co-investigator, 2014–2017

Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2)

Co-investigator, 2014–

DRCRnet: Genes in Diabetic Retinopathy Project

Co-investigator, 2012–

DRCRnet Protocol S. Prompt panretinal photocoagulation versus intravitreal ranibizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy

Co-investigator, 2012–2017

Home vision monitoring in AREDS2 for progression to neovascular age-related macular degeneration

Co-investigator, 2011–2013

DRCRnet Protocol M. Effect of diabetes education during retinal ophthalmology visits on diabetes control

Co-investigator, 2011–2015

DRCRnet Protocol R. Phase II evaluation of topical NSAIDS on eyes with non-central involved DME

Co-investigator, 2011–2013

DRCRnet Protocol N. An evaluation of intravitreal ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy

Co-investigator, 2010–2012

DRCRnet Protocol O. Comparison of time-domain OCT and spectral domain OCT retinal thickness measurement in diabetic macular edema

Co-investigator, 2009–2010

Age-Related Eye Disease Study 2

Co-investigator, 2006–2012

DRCRnet Protocol H. A Phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: bevacizumab (Avastin)

Co-investigator, 2006–2008

DRCRnet Protocol E. A pilot study of peribulbar triamcinolone acetonide for diabetic macular edema

Co-investigator, 2005–2007

Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

Co-investigator, 2005–2007

DRCRnet Protocol B. A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema

Co-investigator, 2004–2007

DRCRnet) Protocol #1A. A pilot study of laser photocoagulation for diabetic macular edema

Co-investigator, 2003–2007

Family Investigation of Nephropathy and Diabetes – FIND (National Institute of Diabetes and Digestive and Kidney Diseases/NIH)

Co-investigator/Study Ophthalmologist, 2000–

Epidemiology of Diabetes Interventions and Complications Trial – EDIC (National Institute of Diabetes and Digestive and Kidney Diseases/NIH)

Co-investigator, 1998–

Complications of Age-related Macular Degeneration Prevention Trial – Laser treatment of drusen – CAPT

Co-investigator, 1998–2007

Other National Clinical Trials

Phase III randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and Lucentis in subjects with neovascular age-related macular degeneration

Principal investigator, 2018–

Ocriplasmin for treatment of systematic vitreomacular adhesion including macular hole (OASIS)

Principal investigator, 2011–2014

A randomized, placebo controlled, double-masked, multicenter trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion

Principal investigator, 2008–2010

A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin for Vitreous Injection III) Trial

Principal investigator, 2007–2009

COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)

Principal investigator, 2007–2008

FVF3689g (SAILOR): A Phase IIIb, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization

(CNV) secondary to age-related macular degeneration (AMD)

Principal investigator, 2006–2007

Protocol FVF3426g (HORIZON): An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) who have completed the treatment phase of a Genentech-sponsored ranibizumab study

Principal investigator, 2006–2007

Cand5 Anti-VEGF RNAi Evaluation (CARE): Dose comparison of Cand5 for subfoveal choroidal neovascularization associated with wet age-related macular degeneration

Principal investigator, 2005–2007

An open label study for the evaluation of tolerability of four dose levels of Cand5 (RNA-interference) administered by single intravitreal injection in patients with wet age-related macular degeneration

Principal investigator, 2005–2007

RNAi Assessment of Cand5 in Diabetic Macular Edema (RACE)

Principal investigator, 2005–2007

The effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography

Principal investigator, 2005–2011

A randomized, double-masked, placebo controlled, parallel group, multi-center, dose-ranging study of denufosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment

Principal investigator, 2004–2005

Protocol FVF2587g: a Phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFabv2 (ranibizumab) compared with verteporfin (Visudyne®) photodynamic therapy in subjects with predominantly classic neovascular age-related macular degeneration

Principal investigator, 2003–2006

Intravitreal Steroid Injection Studies (ISIS)

Principal investigator, 2002–2006

Phase IIa masked study of OPT-302, a VEGF-C and VEGF-D inhibitor, in combination with aflibercept for persistent central-involved DME. (Opthea)

Co-investigator, 2019–

Phase II/III multicenter, randomized, double-masked, parallel-group, placebo-controlled study to investigate the safety, pharmacokinetics, tolerability, and efficacy of oral ALK-001 in geographic atrophy secondary to AMD

Co-investigator, 2019–

Phase II, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with nAMD (LUCERNE)

Co-investigator, 2019–

Phase III, multicenter, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of conbercept intravitreal injection in subjects with neovascular age-related macular degeneration (PANDA)

Co-investigator, 2019–

Phase III study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy secondary to AMD

Co-investigator, 2019–

Randomized, double masked, uncontrolled, multicenter phase I/II study to evaluate safety and tolerability of PAN-90806 eye drops, suspension in treatment-naïve participants with neovascular age-related macular degeneration (AMD)

Co-investigator, 2018–2019

Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (YOSEMITE)

Co-investigator, 2018–

Phase 3, randomized, double-masked, multicenter, controlled study to evaluate the efficacy and safety of brolocizumab in treatment of patients with visual impairment due to diabetic macular edema (KESTREL)

Co-investigator, 2018–

Phase 3, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with geographic atrophy secondary to AMD

Co-investigator, 2018–

Phase 2b, randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura™ (anti-c5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration

Co-investigator, 2018–

Phase 2, double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe nonproliferative diabetic retinopathy ((TIME-2b)

Co-investigator, 2017–

Phase 2, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration

Co-investigator, 2016–2017

Randomized, double-masked, placebo-controlled, dose-finding, non-inferiority study of X-82 plus prn intravitreal (IVT) anti-VEGF compared to prn IVT anti-VEGF monotherapy in neovascular AMD

Co-investigator, 2016–2018

Phase III multicenter randomized, sham controlled, study to determine the safety and efficacy of Renexus® in macular telangiectasia type 2 (NTMT-03-A)

Co-investigator, 2017–

Efficacy and safety study of squalamine ophthalmic solution in subjects with neovascular AMD (MAKO)

Co-investigator, 2016–

Phase 1, dose-escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of OPT-302 in combination with ranibizumab in subjects with wet AMD

Co-investigator, 2016–2017

Phase 3, double masked study of safety and efficacy of abicipar pegol in patients with neovascular age-related macular degeneration

Co-investigator, 2015–2018

Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration

Co-investigator, 2015–2018

Phase 3, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration (PROXIMA)

Co-investigator, 2015–2018

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B PEGylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2015–2017

An 18-month, Phase 2a, open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB PEGylated aptamer)

Co-investigator, 2015–2017

A study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy (EXPOSURE)

Co-investigator, 2015–2017

LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration

Co-investigator, 2015–2016

A study investigating the efficacy and safety of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (CHROMA)

Co-investigator, 2014–2018

Phase 2, multi-center study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist with ranibizumab in adults with diabetic macular edema

Co-investigator, 2014–2015

Phase 2, multicenter randomized clinical trial of ciliary neurotrophic factor (CNTF) for macular telangiectasia type 2 (MacTel)

Co-investigator, 2013–

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B PEGylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2013–2017

Phase 2b/3, multicenter, randomized, double-masked, dose-ranging study comparing the efficacy and safety of emixustat hydrochloride (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry age-related macular degeneration (SEATTLE)

Co-investigator, 2013–2016

Prospective, randomized, double-masked, multicenter, two-arm study comparing the efficacy and safety of ESBA1008 versus Eylea® in subjects with exudative age-related macular degeneration

Co-investigator, 2013–2014

Prospective, two-cohort, single-masked study to evaluate the effect of ESBA1008 applied by microvolume injection or infusion in subjects with exudative age-related macular degeneration

Co-investigator, 2013

Efficacy and safety of squalamine lactate eye drops in subjects with neovascular (wet) age-related macular degeneration

Co-investigator, 2012–2015

Safety and efficacy study of gevokizumab to treat active non-infectious uveitis (EYEGUARD™-A)

Co-investigator, 2012–2015

Safety and efficacy study of gevokizumab to treat non-infectious uveitis controlled with systemic treatment (EYEGUARD™-C)

Co-investigator, 2012–2015

Single and repeat dose study of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration

Co-investigator, 2012

Phase 1, multicenter open-label safety and tolerability clinical trial of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia Type 2 (MacTel)

Co-investigator, 2011–2016

A study of safety, tolerability, and evidence of activity of FCFD4514S administered monthly or every other month to patients with geographic atrophy

Co-investigator, 2011–2013

Multicenter, 2 stage (open label, dose escalation, followed by masked, randomized) single dose study of the safety and efficacy of AGN-208397 in patients with macular edema (ME) associated with retinal vein occlusion (RVO)

Co-investigator, 2011–2012

Dose-ranging study of pazopanib to treat neovascular age-related macular degeneration

Co-investigator, 2010–2011

Phase 1a, multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of FCFD4514S in patients with geographic atrophy

Co-investigator, 2009–2010

Phase 3, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration (HARBOR)

Co-investigator, 2009–2012

Geographic Atrophy Treatment Evaluation (GATE) Study

Co-investigator, 2009–2012

Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion

Co-investigator, 2009–2012

Randomized, double-masked, placebo-controlled, add-on study to assess the efficacy of oral aliskiren 300 mg once daily for diabetic macular edema

Co-investigator, 2009–2010

Natural History of Geographic Atrophy Progression (GAP) Study

Co-investigator, 2008–2009

Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy

Co-investigator, 2008–2010

Phase 1, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD

Co-investigator, 2008–2012

Anecortave acetate for treatment of steroid-induced intraocular pressure (IOP) elevation

Co-investigator, 2008–2009

A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)

Co-investigator, 2007–2012

Phase 2, randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration

Co-investigator, 2007–2010

Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis[®]) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)

Co-investigator, 2007–2009

Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC) study comparing preferential hyperacuity perimetry (PHP) with supervised Amsler grid in detecting AMD for earlier treatment in high-risk fellow eyes

Co-investigator, 2007–2009

Phase 1, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF PEGylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD (Ophthotech 1000)

Co-investigator, 2007–2008

A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 μ g dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema

Co-investigator, 2007–2008

OMEGA: A randomized, double-masked, dose-ranging, multi-center, phase 2 study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration

Co-investigator, 2007–2008

Denali: a 24-month randomized, double-masked, controlled, multicenter, phase 3B study assessing safety and efficacy of verteporfin (Visudyne® photodynamic therapy administered in conjunction with ranibizumab (Lucentis®) versus ranibizumab (Lucentis®) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2007–2008

Macugen (pegaptanib sodium) for angioid streaks complicated by choroidal neovascular membrane

Co-investigator, 2006–2010

Macugen (pegaptanib sodium) for pathological myopia complicated by subfoveal choroidal neovascularization

Co-investigator, 2006–2010

Phase 4, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement (Eyeteck 1023)

Co-investigator, 2006–2008

Efficacy and safety of intravitreal injection of Macugen for recent onset neovascular lesions of AMD

Co-investigator, 2006–2008

Phase 3, multicenter, masked, randomized, sham controlled trial to assess the safety and efficacy of DEX PS DDS (700 micrograms, 350 micrograms, or placebo) in the treatment of patients with diabetic macular edema

Co-investigator, 2006–2008

Natural and family history studies of macular telangiectasia (MacTel)

Co-investigator, 2005–

Phase 3, multicenter, masked, randomized, sham controlled trial to assess the safety and efficacy of DEX PS DDS (700 micrograms, 350 micrograms, or placebo) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion

Co-investigator, 2005–2008

Interval Dose Evaluation of Anecortave Acetate (IDEAA) Study

Co-investigator, 2005–2008

Protocol OT-551-002: a multi-center, double-masked, randomized, vehicle-controlled, parallel group evaluation of the safety and efficacy of OT-551 ophthalmic solution to prevent formation or delay progression of nuclear cataract formation in post-vitrectomy patients

Co-investigator, 2005–2007

A Phase 3 prospective, randomized, double-masked, sham controlled, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on fovea thickening in patients with exudative subfoveal age-related macular degeneration (Eyetechnology 1009)

Co-investigator, 2005–2007

Ocular side effects of Cialis vs. Viagra vs. placebo

Co-investigator, 2005–2006

Phase 3, dose-ranging, open-labeled, multi-center study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopia

Co-investigator, 2005–2006

A 24-month randomized, double-masked, sham controlled, multicenter, phase 3B study comparing photodynamic therapy with verteporfin (Visudyne®) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne® plus intravitreal pegaptanib (Macugen®) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2005–2006

Phase 4, randomized, active controlled, double-masked, single dummy, to compare the safety and efficacy of Macugen every 6 weeks plus sham PDT to Macugen every 6 weeks with PDT in patients with predominantly classic CNV (Eyetechnology 1012)

Co-investigator, 2005–2006

Protein Kinase C β Inhibitor Study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema

Co-investigator, 2004–2010

Anecortave Acetate Risk-Reduction Trial

Co-investigator, 2004–2008

A Phase 2 randomized, double-masked, safety, efficacy, and pharmacokinetics study of Macugen vs. placebo given every 6 weeks for 30 weeks for vision loss due to macular edema secondary to CRVO (Eyetechnology 1011)

Co-investigator, 2004–2006

A Phase 1/2, randomized, masked, single and multiple-dose, sequential dose-escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration

Co-investigator, 2004–2006

Multicenter, open label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate (Seroquel™) and risperidone (Risperdal™) in the long term treatment of patients with schizophrenia or schizoaffective disorder

Co-investigator/Evaluating ophthalmologist, 2003–2008

Visudyne Patient Registry

Co-investigator, 2003–2007

The Implantable Miniature Telescope (IMT™) in patients with central vision impairment associated with age-related macular degeneration or Stargardt's macular dystrophy

Co-investigator, 2003–2005

A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1 mg/eye and 3 mg/eye intravitreal injections of pegaptanib sodium (anti-VEGF PEGylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (Eyeteck 1006)

Co-investigator, 2002–2006

A Phase 2 randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (anti-VEGF PEGylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula (Eyeteck 1005)

Co-investigator, 2002–2003

Fluocinolone Acetonide in Diabetic Macular Edema (FAME 4) Study: A multicenter, randomized, masked, controlled study to evaluate the safety and efficacy of Retisert™, an intravitreal fluocinolone acetonide implant, in the treatment of patients with diabetic macular edema

Co-investigator, 2001–2007

Phase 2/3 randomized, double-masked, controlled, dose-ranging, multicenter comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF PEGylated aptamer) given every 6 weeks for 54 weeks in patients with age-related macular degeneration (Eyeteck 1004)

Co-investigator, 2001–2005

Oculex Study: A phase 2 randomized, multicenter, dose-ranging, controlled, parallel-group trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS®) in the treatment of persistent macular edema

Co-investigator, 2001–2003

Visudyne™ Early Retreatment (VER) Study: Multicenter, randomized, parallel group, double-masked, controlled phase 3b, 2-year study comparing the efficacy and safety of Visudyne™ therapy with early retreatment to standard treatment in predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2001–2003

Transpupillary thermotherapy for the treatment of subfoveal occult choroidal neovascular membranes in patients with age-related macular degeneration

Co-investigator, 2000–2004

Verteporfin in Age-related Macular degeneration (VAM) Study: Open-label, multicenter,

safety study of the treatment of predominantly classic choroidal neovascularization secondary to age-related macular degeneration using photodynamic therapy with verteporfin for injection

Co-investigator, 1999–2000

Evaluation of safety and duration of efficacy of anecortave acetate sterile suspension versus placebo following a single sub-Tenon's injection for the inhibition of neovascularization in patients with exudative age-related macular degeneration

Co-investigator, 1998–2001

Verteporfin in Photodynamic Therapy Study

Co-investigator, 1998–2003

Protein kinase C β inhibitor studies: Diabetic Macular Edema Study and Diabetic Retinopathy Study

Co-investigator, 1998–2002

Metalloprotease inhibitor for subfoveal choroidal neovascular membranes in patients with macular degeneration

Co-investigator, 1998–2001

SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND SYMPOSIA

1. Virtual Training in Global Ophthalmology. Cleveland Ophthalmological Society. Cleveland, Ohio, February 9, 2021.
2. Retinal detachment. Optometric Retinal Update Seminar. Westlake, Ohio, June 13, 2019.
3. Anterior segment neovascularization and neovascular glaucoma. Optometric Retinal Update Seminar. Westlake, Ohio, June 13, 2019.
4. “Reattached, but....” Cole Eye Institute North Coast Retina Symposium X. June 1, 2019.
5. Surviving a medical malpractice case. Ohio Ophthalmological Society Annual Meeting. Columbus, Ohio, February 23, 2019.
6. Retinal detachment secondary to posterior uveitis. Cleveland Ophthalmological Society. Cleveland, Ohio, December 11, 2018.
7. There it goes: IOL dislocation and management. The Vermont Ophthalmological Society 2018 Retina Symposium. Vergennes, Vermont, October 7, 2018.
8. Clinical trials and wet AMD. Seminar for Ophthalmologists. Cleveland, Ohio, September 27, 2018.
9. There it goes: IOL dislocation and replacement. Optometric Retinal Update Seminar. Cleveland, Ohio, June 7, 2018.

10. There it goes: IOL dislocation and replacement. Cleveland Ophthalmological Society. Cleveland, Ohio, April 10, 2018.
11. Retinal surgery case selection and safety in ASC vs. hospital. Mediterranean Retina VII Meeting. Sorrento, Italy. October 13, 2017.
12. Ocular complications following intraocular injection of elevated dose of cefuroxime. American Eye Study Club 60th Annual Meeting. Dana Point, California. July 31, 2017.
13. Facility location and retinal surgery - case selection & safety. Optometric Retinal Update Seminar. Cleveland, Ohio. June 8, 2017.
14. Case presentation. Cole Eye Institute North Coast Retina Symposium VIII. June 2-3, 2017.
15. Melchioris A, Zgrabik M, Hornik J, Miller DG. Ocular complications following intracameral injection of an elevated dose of cefuroxime during phacoemulsification surgery. Presentation Number 5589. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Baltimore, Maryland. May 11, 2017.
16. Patel D, Shah A, Melchioris A, Miller DG. Evaluation of visual acuity and acute retinal changes following intravitreal injection of ocriplasmin. Presentation Number 1591. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Baltimore, Maryland. May 8, 2017.
17. Live Surgery Faculty Member. Vit-Buckle Society Annual Meeting. Las Vegas, Nevada. April 7, 2017.
 - Awarded *Best Wrangler*
18. Clinical trials in macular disease. Cleveland Ophthalmological Society. Cleveland, Ohio. December 13, 2016.
19. Facility location and retinal surgery. American Eye Study Club Meeting. Amelia Island, Florida. August 2016.
20. Retinal surgical techniques and video potpourri. Optometric Retinal Update Seminar. Cleveland, Ohio. June 16, 2016.
21. FA and OCT interpretation for retinal diseases. Optometric Retinal Update Seminar. Akron, Ohio. April 16, 2016.
22. Moderator, Scientific Session III. American Eye Study Club Meeting. Mackinac Island, Michigan. July 30, 2015.
23. Retina Associates cases of 2015. Optometric Retinal Update Seminar. Cleveland, Ohio. June 18, 2015.

24. Miller DG, Miller AG, Rao LJ, Rowland DY, Hornik JH. The effect of patient-specific prescriptions on selection of anti-VEGF agents. American Eye Study Club. Vail, Colorado. July 2014.
25. Home monitoring for early detection of wet macular degeneration. Optometric Retinal Update Seminar. Cleveland, Ohio. June 26, 2014.
26. Bevacizumab vs. ranibizumab in the treatment of diabetic macular edema. Optometric Retinal Update Seminar. Beachwood, Ohio. March 20, 2014.
27. Bevacizumab vs. ranibizumab in the treatment of diabetic macular edema. Squaw Valley Retina Symposium. The Ritz-Carlton, Lake Tahoe. Truckee, California. February 6-9, 2014.
28. Use of surgical adjuncts for visualization during vitrectomy surgery. Cleveland Ophthalmological Society. Cleveland, Ohio. October 15, 2013.
29. Lucentis vs. Avastin for the treatment of diabetic macular edema. American Eye Study Club Annual Meeting. Atlantis Resort. Paradise Island, Bahamas. August 2, 2013.
30. Flashes and floaters. Optometric Retinal Update Seminar. Westlake, Ohio. June 18, 2013.
31. 1) Retinal surgery in the ambulatory surgical center. 2) A case of posterior uveitis-associated retinal detachment. 3) Chemical vitrectomy: microplasmin for the treatment of vitreoretinal traction. American College of Eye Surgeons/Surgical Excellence in Eyecare Caribbean Eye Meeting. San Juan, Puerto Rico. February 8-12, 2013.
32. Retinal update on anti-VEGF therapy (with Drs. Coney, Novak, Rao, Schartman, and Zegarra). Ophthalmologists' Update Seminar. Vermilion, Ohio, December 20, 2012.
33. Selection and implementation of electronic health record system. Cleveland Ophthalmological Society. Cleveland, Ohio. December 11, 2012.
34. Retinal update on anti-VEGF therapy (with Drs. Coney, Miller, Novak, Rao, Schartman, and Zegarra). Ophthalmologists' Update Seminar. Vermilion, Ohio, August 12, 2012.
35. Subspecialty boarding in ophthalmology: a medico-legal issue? American Eye Study Club Annual Meeting. The Grand Del Mar Resort. San Diego, California. July 31, 2012.
36. Retinal surgical cases: a video presentation. Optometric Retinal Update Seminar. Westlake, Ohio. June 5, 2012.
37. Retinal surgery in an ambulatory surgery center. The Many Faces of a Retina Practice, American Academy of Ophthalmic Executives Seminar, American Academy of Ophthalmology Annual Meeting. Orlando, Florida. October 22, 2011.
38. Introducing electronic health records to a retina practice. Cleveland Ophthalmological Society. Cleveland, Ohio. October 11, 2011.

39. Implementation of retinal electronic health records system. Retinal Update Seminar. Westlake, Ohio. June 28, 2011.
40. Unresponsive wet AMD. North Coast Retina Symposium. Cole Eye Institute, Cleveland Clinic Foundation. Cleveland, Ohio. May 13, 2011.
41. Chemical vitrectomy. Optometric Retinal Update Seminar. Beachwood, Ohio. March 3, 2011.
42. Recent developments in the etiology, treatment, and research of age-related macular degeneration. Cleveland Eye Clinic Update on Macular Degeneration, OCT Imaging, and Retinal Disease. Cleveland, Ohio. January 26, 2011.
43. Chemical vitrectomy. Cleveland Ophthalmological Society. Cleveland, Ohio. October 12, 2010.
44. Neovascular glaucoma. Optometric Retinal Update Seminar. Westlake, Ohio. August 19, 2010.
45. Surgery for neovascular glaucoma: two birds with one stone? American Eye Study Club Annual Meeting. Nemacolin Woodland Resort; Farmington, Pennsylvania. August 3–7, 2010.
46. Singerman LJ, Novak MA, Miller DG, Coney JC, et al. Ranibizumab treatment for pigment epithelial detachment (PED) in age-related macular degeneration (AMD). Retina Congress 2009, Combined Meeting of the American Society of Retina Specialists, The Macula Society, and The Retina Society. New York, New York. September 30–October 4, 2009.
47. Coney JM. Retina surgery videos (with David G. Miller, MD). National Medical Association Annual Meeting. Las Vegas, Nevada. July 25–29, 2009.
48. Chemical vitrectomy: clinical trial of intravitreal microplasmin. American Eye Study Club. Colorado Springs, Colorado. July 23, 2009.
49. Participant, Practice Management Symposium. American Eye Study Club. Colorado Springs, Colorado. July 24, 2009.
50. Interesting retinal cases. Northeast Ohio Vision Source meeting. Ashland, Ohio. July 8, 2009.
51. Chemical vitrectomy: clinical trial of intravitreal microplasmin. Optometric Retinal Update Seminar. June 18, 2009.
52. Berlon NR, Miller DG, Novak MA, Pendergast SD, Coney JM. Safety and efficacy of 25-gauge vitrectomy surgery by experienced vitreoretinal surgeons. Association for Research in Vision and Ophthalmology Annual Meeting. Program # 5202. Fort Lauderdale, Florida. May 7, 2009.

53. Retinal imaging (with H. Zegarra). Optometric Continuing Education Program and Open House. Lorain, Ohio. January 13, 2009.
54. Surgical techniques for epiretinal membrane removal. Retinal Update for Ophthalmologists. Cleveland, Ohio. November 20, 2008.
55. Small-gauge vitrectomy in our practice: expanded indications. Optometric Retinal Update Seminar. Westlake, Ohio. July 15, 2008
56. Small-gauge vitrectomy in our practice: expanded indications. 8th Congress of the Croatian Ophthalmological Society. Sibenik, Croatia. May 8–10, 2008.
57. 25-gauge surgery for macular hole repair. American Eye Study Club, 50th Annual Meeting. Ritz Carlton Bachelor Gulch, Beaver Creek, Colorado. July 22–26, 2007.
58. Update on diabetic retinopathy: diagnosis and treatment. Optometric Retinal Update Seminar. Westlake, Ohio. July 17, 2007.
59. Macular hole repair. Optometric Retinal Update Seminar. Beachwood, Ohio. February 15, 2007.
60. Results of surgical management of senile macular holes by 25-gauge trans-conjunctival sutureless vitrectomy compared to standard vitrectomy systems. Annual meeting of the American Society of Retina Specialists. Cannes, France. September 8–13, 2006.
61. Treating macular degeneration with ranibizumab (Lucentis). Optometric Retinal Update Seminar. Westlake, Ohio. August 10, 2006.
62. Vitrectomy surgery. Parma Community General Hospital Retinal Update. Parma, Ohio. March 21, 2006.
63. Angiography in macular degeneration: Avastin and Lucentis. Optometric Retinal Update Seminar. Beachwood, Ohio. February 9, 2006.
64. Pharmacotherapy for age-related macular degeneration. Michigan Ophthalmological Society. Detroit, Michigan. November 16, 2005.
65. Update on treatments for age-related macular degeneration. Buffalo Eye Club. Buffalo, New York. October 27, 2005.
66. Modern retinal imaging. Optometric Retinal Update Seminar. Westlake, Ohio. August 11, 2005
67. Flashes & floaters. Optometric Retinal Update Seminar. Beachwood, Ohio. February 15, 2005
68. Cataract surgery and retinal disease. Optometric Retinal Update Seminar. Westlake, Ohio. July 29, 2004.

69. Retinal detachment: principles and treatment. Ohio Ophthalmological Society Annual Meeting. March 20, 2004.
70. Cataract surgery and macular disease. Ohio Ophthalmological Society Annual Meeting. March 20, 2004.
71. Co-chair, Cleveland Ophthalmological Society. Cleveland, Ohio. February 10, 2004.
72. Photodynamic therapy and macular degeneration. Optometric Continuing Medical Education. Vermilion, Ohio. December 2003.
73. Retinal complications of toxoplasmosis retinitis. Cleveland Ophthalmological Society. Cleveland, Ohio. October 2003.
74. Cataract surgery and retinal diseases. Cleveland Ophthalmological Society. Cleveland, Ohio. October 2003.
75. Update on diabetic retinopathy. East-West Eye Conference. Cleveland, Ohio. October 2003.
76. Diagnosis of vitreous opacities (vitreous amyloidosis). Cleveland Ophthalmological Society. Cleveland, Ohio. April 15, 2003.
77. Pharmacotherapy of treatment of diabetic retinopathy. Optometric Retinal Update Seminar. Westlake, Ohio. August 12, 2003.
78. Implantable miniature telescope. Optometric Retinal Update Seminar. Beachwood, Ohio. February 20, 2003.
79. Update on macular degeneration. Cuyahoga Community College Encore Campus. Cleveland, Ohio. November 1, 2002.
80. Posterior segment complications and other challenges of LASIK in the high myope (with Mohinder K. Gupta, MD, co-instructor). American Society of Cataract and Refractive Surgery. Philadelphia, Pennsylvania. June 4, 2002.
81. Intravitreal triamcinolone acetonide for the treatment of macular edema. Cleveland Ophthalmological Society. Cleveland, Ohio. February 12, 2002.
82. The future of retinal care. Ohio Optometric Society. The Symposium of the Future. Cleveland, Ohio. February 4, 2002.
83. The myopic retina. Optometric Refractive Surgery Society, 6th Annual Symposium; August 2001. 1) Update on Diabetic Retinopathy; 2) Update on Age-related Macular Degeneration; and 3) Retinal Complications of High Myopia. Society for Excellence in Eyecare Conference; Aruba. January 27–31, 2002.
84. Update on photodynamic therapy with Visudyne. State University of New York, Visiting Professor. May 2001.

85. Unusual presentation of posterior scleritis. Cleveland Ophthalmological Society. Cleveland, Ohio. 2001.
86. Controversy in the management of posterior segment trauma. Cleveland Ophthalmological Society. Cleveland, Ohio. 2000.
87. Surgical management of macular hole. East-West Eye Conference. Cleveland, Ohio. 1999.
88. What's new in macula? East-West Eye Conference; Cleveland, Ohio, 1999.
89. Update on the management of age-related macular degeneration. East-West Eye Conference. Cleveland, Ohio. 1999.
90. Treatment of macular hole. Massachusetts Eye and Ear Infirmary Seminar, Surgical Advances in Ophthalmology. 1998.
91. Presumed ocular histoplasmosis syndrome and corticosteroids. Indiana University. 1997.
92. The use of corticosteroids in the treatment of histoplasmosis-related subfoveal choroidal neovascularization. Association for Research and Vision in Ophthalmology Annual Meeting. Fort Lauderdale, Florida, 1997.
93. Patient satisfaction with orbicectomy in the treatment of blepharospasm. Indiana University, 1996.

ONLINE PRESENTATIONS

1. The Basics of Vitrectomy for Rhegmatogenous Retinal Detachment Repair. Live Surgical Demonstration. February 22, 2021. <https://cybersight.org/portfolio/live-surgical-demonstration-the-basics-of-vitrectomy-for-rhegmatogenous-retinal-detachment-repair/>
2. Proliferative diabetic retinopathy. Live Surgical Demonstration: proliferative diabetic retinopathy surgical demonstration. July 15, 2019. <https://cybersight.org/portfolio/live-surgical-demonstration-proliferative-diabetic-retinopathy-surgical-demonstration/>
3. Retinal vein occlusion. Lecture. April 11, 2019. <https://cybersight.org/portfolio/lecture-retinal-vein-occlusion/>
4. Diabetic retinopathy. Lecture. April 11, 2019. <https://cybersight.org/portfolio/lecture-diabetic-retinopathy/>
5. Basics of vitrectomy surgery - Part II. Live Surgical Demonstration. September 10, 2018. <https://cybersight.org/portfolio/live-surgical-demonstration-the-basics-of-vitrectomy-surgery-part-ii/>
6. Basics of vitrectomy surgery – Part I. Live Surgical Demonstration. April 10, 2017. <https://cybersight.org/portfolio/live-surgical-demonstration-the-basics-of-vitrectomy-surgery/>

7. Macular hole surgery. Live Surgical Demonstrations: the basics of macular hole surgery. February 24th, 2020. <https://cybersight.org/portfolio/surgery-live-surgical-demonstration-basics-of-macular-hole-surgery/>

PUBLICATIONS

Journal Articles

1. Miller, Alexander G. BS; Obri, Mark S. BS; Miller, David G. MD. Preoperative Telephone Medical Clearance for Ophthalmic Surgeries, *Journal of Cataract & Refractive Surgery*: March 09, 2021 - Volume Publish Ahead of Print - Issue - doi:10.1097/j.jcrs.0000000000000548
2. Alexander G Miller, Christian X Miller, Mark Obri, Douglas Y Rowland, Joan H Hornik, David G Miller. Correlation of Medicare Patient Volume and Online Ratings for Retinal Physicians. *Acta Scientific Ophthalmology* 3.1(2019): 19-21.
3. Miller, A.G., Chandra R., Pophal C., Schartman J.P., Hornik J.H. & Miller D.G., Efficacy of Macular Hole Surgery in Patients with Idiopathic Macular Telangiectasia Type 2, *Ophthalmology Retina* (2019), doi: <https://doi.org/10.1016/j.oret.2019.11.017>.
4. Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Elliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial. *Ophthalmology*. 2018 Oct 4. pii: S0161-6420(18)31427-1. doi: 10.1016/j.ophtha.2018.09.041. [Epub ahead of print]
5. Yu JJ, Agrón E, Clemons TE, Domalpally A, van Asten F, Keenan TD, Cukras C, Chew EY; Age-Related Eye Disease Study 2 Research Group. Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration: Age-Related Eye Disease Study 2 report no. 17. *Ophthalmology*. 2019;126:261-273.
6. Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Progression of geographic atrophy in age-related macular degeneration: AREDS2 Report Number 16. *Ophthalmology*. 2018;125:1913-1928.
7. Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC; Diabetic Retinopathy Clinical Research Network. Plasma vascular endothelial growth factor concentrations after intravitreal anti-vascular endothelial growth factor therapy for diabetic macular edema. *Ophthalmology*. 2018;125:1054-1063.
8. Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, Ziegler G, Cleary PA, Brunzell JD; DCCT/EDIC Research Group. Impact of excessive weight gain on cardiovascular outcomes in Type 1 Diabetes: results from the Diabetes Control and

- Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes Care*. 2017;40:1756-1762.
9. Lee AC, Opremcak EM, Hunt C, Astruc Jr JA, Toussaint B, Miller DG, Busquets MA, Ferrone PJ. Severe corneal complications associated with corneal lubricant used during surgery. *Journal of VitreoRetinal Diseases*. 2017;1:187-190.
 10. DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM. Frequency of evidence-based screening for retinopathy in Type 1 diabetes. *N Engl J Med*. 2017 Apr 20;376:1507-1516.
 11. Sciulli H, Miller CW, Rao LJ, Hornik JH, Rowland DY, Miller DG. Retinal surgery in ambulatory surgery centers versus hospital outpatient departments. *Ophthalmology Retina* 2017;1:563-564.
 12. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD; DCCT/EDIC Research Group, Natarajan R. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. *Proc Natl Acad Sci U S A*. 2016;113(21):E3002-11.
 13. Lenherr SM, Clemens JQ, Braffett BH, Cleary PA, Dunn RL, Hotaling JM, Jacobson AM, Kim C, Herman W, Brown JS, Wessells H, Sarma AV; DCCT/EDIC Research Group. Glycemic control and urinary tract infections in women with type 1 diabetes: Results from the DCCT/EDIC. *J Urol*. 2016;196:1129-1135.
 14. Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:865-875.
 15. Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Angiographic cystoid macular edema and outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:858-864.
 16. AREDS2 Research Group, Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Sperduto RD, Ferris FL 3rd, Chew EY. The association of statin use with cataract progression and cataract surgery: The AREDS2 Report Number 8. *Ophthalmology*. 2016;123:916-917.
 17. Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME; Diabetic Retinopathy Clinical Research Network. Persistent macular thickening after ranibizumab treatment. *JAMA Ophthalmol*. 2016 Mar 1;134:278-285.
 18. Wells JA, Glassman AR, Jampol LM, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year

- efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. *JAMA Ophthalmol.* 2016;134:127-134.
19. Holfinger S, Miller AG, Rao LJ, Rowland DY, Hornik JH, Miller DG. Effect of regulatory requirement for patient-specific prescriptions for off-label medications on the use of intravitreal bevacizumab. *JAMA Ophthalmol.* 2016 Jan 1;134:45-48.
 20. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. *JAMA.* 2015 Nov 13:1-11.
 21. Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE Study Report 15. *JAMA Ophthalmol.* 2015 Sep;133:1022-1029.
 22. Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA; Diabetic Retinopathy Clinical Research Network. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycemic control: a randomized clinical trial. *JAMA Ophthalmol.* 2015;133:888-896.
 23. Eny KM, Orchard TJ, Miller RG, Maynard J, Grant DM, Costacou T, Cleary PA, Braffett BH, Paterson AD; DCCT/EDIC Research Group. Caffeine consumption contributes to skin intrinsic fluorescence in type 1 Diabetes. *Diabetes Technol Ther.* 2015;17:726-734.
 24. Bressler SB, Almkhatar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M; Diabetic Retinopathy Clinical Research Network Investigators. Repeated intravitreal ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. *JAMA Ophthalmol.* 2015;133:589-597.
 25. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med.* 2015 Mar 26;372:1193-1203.
 26. Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, Singerman L, Schwartz SD, Peachey NS, Bird AC; MacTel-CNTF Research Group. Ciliary neurotrophic factor (CNTF) for macular telangiectasia Type 2 (MacTel): Results from a phase I safety trial. *Am J Ophthalmol.* 2015;159:659-666.
 27. Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, Kampik A, Jaffe GJ, Toth CA; MIVI-TRUST Study Group. Efficacy of intravitreal ocriplasmin for

- treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. *Ophthalmology*. 2015;122:117-122.
28. Simpson CL, Wojciechowski R, Oexle K, Murgia F, Portas L, Li X, Verhoeven VJ, et al; DCCT/EDIC Research Group. Genome-wide meta-analysis of myopia and hyperopia provides evidence for replication of 11 loci. *PLoS One* 2014 Sep 18;9(9):e107110. doi: 10.1371/journal.pone.0107110. eCollection 2014.
 29. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. *JAMA Ophthalmol*. 2013;131:1033-1040.
 30. Danis RP, Domalpally A, Chew EY, Clemons TE, Armstrong J, SanGiovanni JP, Ferris FL 3rd; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). *Invest Ophthalmol Vis Sci*. 2013;54:4548-4554.
 31. Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. *Ophthalmology*. 2013;120:1046-1056.
 32. Cheng CY, Schache M, Ikram MK, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions, and Complications Research Group. Nine loci for ocular axial length identified through genome-wide association studies, including shared loci with refractive error. *Am J Hum Genet* 2013;93:264-277.
 33. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. *JAMA Ophthalmol*. 2013;131:283-293.
 34. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, Glassman AR, Maturi RK, Melia M. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology*. 2012;119:2312-2318.
 35. Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. *N Engl J Med*. 2012;367:606-615.
 36. Sallo FB, Leung I, Chung M, Wolf-Schnurrbusch UE, Dubra A, Williams DR, Clemons T, Pauleikhoff D, Bird AC, Peto T; MacTel Study Group. Retinal crystals in type 2 idiopathic macular telangiectasia. *Ophthalmology*. 2011;118:2461-2467.
 37. Schartman JP, Coney JM, Miller DG. Pegaptanib octasodium for the treatment of diabetic macular oedema. *Expert Opinion on Pharmacotherapy*. 2011;12:1317-1323.

38. Gangaputra S, Almuthtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; Diabetic Retinopathy Clinical Research Network. Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. *Invest Ophthalmol Vis Sci.* 2011;52:6168-6173.
39. Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA; SCORE Study Investigator Group. SCORE Study Report #11. Incidences of Neovascular Events in Eyes with Retinal Vein Occlusion. *Ophthalmology.* 2011;118:1364-1372.
40. Diabetic Retinopathy Clinical Research Network; Writing Committee, Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology.* 2011;118:609-614.
41. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, Bressler SB, Ferris FL 3rd, Gupta SK, Haller JA, Lazarus HS, Qin H. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research Network. *Retina.* 2010;30:1488-1495.
42. Danis RP, Scott IU, Qin H, Altaweel MM, Bressler NM, Bressler SB, Browning DJ, Kollman C; For The Diabetic Retinopathy Clinical Research Network. Association of fluorescein angiographic features with visual acuity and with optical coherence tomographic and stereoscopic color fundus photographic features of diabetic macular edema in a randomized clinical trial. *Retina.* 2010;30:1627-1637.
43. Ferris FL 3rd, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research Network. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. *Ophthalmology.* 2010;117:1512-1516.
44. Diabetic Retinopathy Clinical Research Network Writing Committee on behalf of the DRCR.net. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. *Ophthalmology.* 2010;117:1087-1093.
45. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology.* 2010;117:1064-1077.
46. Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, Glassman AR, Ip MS, Miller KM; Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. *Ophthalmology.* 2010;117:946-953.
47. Coney JM, Miller DG. Epiretinal membrane. *Focal Points.* Volume XXVII, Number 5, American Academy of Ophthalmology, 2009.
48. Bhavsar AR, Googe JM Jr, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR; Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis

- after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. *Arch Ophthalmol.* 2009;127:1581-1583.
49. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. *Am J Ophthalmol.* 2009;148:725-732.
50. Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, Kollman C, Kuppermann BD, Stone TW; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. *Arch Ophthalmol.* 2009;127:1566-1571.
51. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol.* 2009;127:1115-1128.
52. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol.* 2009;127:1101-1114.
53. Diabetic Retinopathy Clinical Research Network. The course of response to focal/grid photocoagulation for diabetic macular edema. *Retina.* 2009 Nov-Dec;29:1436-1443.
54. Scott IU, Danis RP, Bressler SB, Bressler NM, Browning DJ, Qin H; Diabetic Retinopathy Clinical Research Network. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema. *Retina.* 2009 May;29:613-617.
55. Browning DJ, Apte RS, Bressler SB, Chalam KV, Danis RP, Davis MD, Kollman C, Qin H, Sadda S, Scott IU; Diabetic Retinopathy Clinical Research Network. Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. *Retina.* 2009 Mar;29:300-305.
56. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology.* 2009;116:1770-1777.
57. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. *Arch Ophthalmol.* 2009;127:245-251.

58. Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd.. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. *Arch Ophthalmol*. 2009;127:132-140.
59. Sun JK, Aiello LP, Stockman M, Cavallerano JD, Kopple A, Eagan S, Qin H, Kollman C, Beck RW, Glassman AR; Diabetic Retinopathy Clinical Research Network. Effects of dilation on Electronic-ETDRS Visual Acuity in diabetic patients. *Invest Ophthalmol Vis Sci*. 2009;50:1580-1584.
60. Glassman AR, Beck RW, Browning DJ, Danis RP, Kollman C; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of optical coherence tomography in diabetic macular edema, with and without reading center manual grading from a clinical trials perspective. *Invest Ophthalmol Vis Sci*. 2009;50:560-566
61. Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial. *Ophthalmology*. 2008;115:1474-1479, 1479.e1-6.
62. Maguire MG, Alexander J, Fine SL; Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial. *Ophthalmology*. 2008;115:1468-1473, 1473.e1-2.
63. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H, Jaeb Center for Health Research and the Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and laser photocoagulation for diabetic macular edema: baseline features. *Retina*. 2008;28:919-930.
64. Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett MER, Kollman C, Li HK, Qin Q, Scott IU; the Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. *Invest Ophthalmol Vis Sci*. 2008;49:1745-1752.
65. Ying G-S, Maguire M, Liu C, Antoszyk A, Complications of Age-related Macular Degeneration Prevention Trial Research Group. Night vision symptoms and progression of age-related macular degeneration (AMD) in the Complications of AMD Prevention Trial. *Ophthalmology*. 2008;115):1876-1882.
66. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK; Diabetic Retinopathy Clinical Research Network. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. *Am J Ophthalmol*. 2008;145:894-901.

67. Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU; Diabetic Retinopathy Clinical Research Network. Diabetic macular edema: what is focal and what is diffuse? *Am J Ophthalmol.* 2008;146:649-655.e1-6.
68. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW; Macular Telangiectasia Research Group. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. *Invest Ophthalmol Vis Sci.* 2008;49:4340-4346.
69. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology.* 2008;115:1447-1449, 1449.e1-10.
70. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology.* 2008;115:1366-1371, 1371.e1.
71. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Kim JE, Pollack JS, Miller DG, Mitra RA, Spaide RF; ISIS Study Group. *Retina.* 2008;28:735-740.
72. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H; Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. *Retina.* 2008;28:36-40.
73. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology.* 2007;114:1860-1867.
74. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. *Ophthalmology.* 2007;114:1190-1196.
75. Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology.* 2007;114:1702-1712.
76. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. *Am J Ophthalmol.* 2007;144:454-456.

77. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology*. 2007;114:525-536.
78. Diabetic Retinopathy Clinical Research Network. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. *Ophthalmology*. 2007; 114:520-525.
79. Diabetic Retinopathy Clinical Research Network. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol*. 2007;125:469-480.
80. Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. *Surv Ophthalmol*. 2007;52 Suppl 1:S79-90.
81. Miller DG, Singerman LJ. Vision loss in younger patients: a review of choroidal neovascularization. *Optom Vis Sci*. 2005;83:316-325.
82. Diabetic Retinopathy Clinical Research Network, Danis RP, Glassman AR, Aiello LP, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Kinyoun JL, Murtha TJ, Topping TM, Shami M, Sharuk GS, Wells JA 3rd. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. *Arch Ophthalmol*. 2006;124:1701-1707.
83. Complications of Age-related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: The Complications of Age-Related Macular Degeneration Prevention Trial. *Ophthalmology*. 2006;113:1974-1986.
84. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. *Ophthalmology*. 2006;113:1508-1521.
85. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. *Ophthalmology*. 2006;113:992-1001.
86. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355:1432-1444.
87. Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. *Retina*. 2005;25:815-827.

88. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med.* 2004;;351:2805-2816.
89. Maguire M; Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology.* 111:1307-1316, 2004.
90. Complications of Age-related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design, and methodology. *Clinical Trials.* 2004;1:91-107.
91. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report no. 4. *Retina.* 2004;24:1-12.
92. Singerman LJ, Miller DG. Pharmacological treatments for AMD. *Rev Ophthalmol.* 10: 88-90, 92, 94; 2003. http://www.revophth.com/index.asp?page=1_422.htm
93. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology.* 2003;110:2372-2383.
94. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P; The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. *Retina.* 2003;23:14-23.
95. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Phase II study results. *Ophthalmology.* 2003;110:979-986.
96. Singerman LJ, Miller DG. Diabetic retinopathy and DME drug trials advance. *Rev Ophthalmol.* 10:124-127, 2002. http://www.revophth.com/index.asp?page=1_204.htm
97. Miller DG, Singerman LJ. The natural history of choroidal neovascularization in high myopia. *Current Opinion in Ophthalmology.* 2001;12:222-224.

98. Martidis A, Miller DG, Ciulla RP, Moorthy RS. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. *J Ocul Pharmacol Ther.* 1999;15:425-42.
99. Miller DG, Lou PL, Kroll AJ, Ryan EA. Surgical management of macular hole. *Int Ophthalmol Clin.* Winter 1999;39:261-274.
100. Miller DG, Ryan EA. Removal of silicone oil. [Letter] *VitreoTech* June 1998;Volume 3
101. Miller DG, Evans R, Blaustein A. Does hydrogen peroxide mediate changes in stunned myocardium? *Clinical Research.* April 1991;39:397A.

Book Chapters

1. Miller DG, Sharma MC, Singerman LJ. Laser treatment of age-related macular degeneration. In Boyd BF, Boyd S (eds.). *Retinal and Vitreoretinal Surgery: Mastering the Latest Techniques.* Panama: Highlights of Ophthalmology Press, 2005, pp. 250-261.
2. Miller DG, Singerman LJ. Key questions for a focused history. In Steidl SM, Hartnett ME (eds.). *Clinical Pathways in Vitreoretinal Disease.* New York: Thieme, 2003, pp 3-12.
3. Miller DG, Singerman LJ. Laser treatment of age-related macular degeneration. In Boyd BF, Boyd S (eds.). *Retinal and Vitreoretinal Surgery: Mastering the Latest Techniques.* Panama: Highlights of Ophthalmology Press, 2002, pp 249-261.
4. Miller DG, Singerman LJ. Diabetic retinopathy: medical considerations. In Saer JB (ed.). *Vitreo-Retinal and Uveitis Update. Proceedings of the New Orleans Academy of Ophthalmology Symposium.* The Hague: Kugler Publications, 1998, pp 239-244.

Abstracts

1. Robertson, Jacobi A.; Abdulaal, Marwan; Moore, Madison T.; Coney, Joseph M.; Platt, Sean; Rao, Llewelyn J.; Miller, David G.; Pendergast, Scott D.; Schartman, Jerome P. Risk and Assessment of COVID-19 in a Retina Ophthalmic Setting. Association for Research in Vision and Ophthalmology Annual Meeting, May 2021.
2. Miller C., Miller A., McCrossin, C., Miller, D., Ozurdex Migration to Anterior Chamber in Patients with Sutured Intraocular Lenses. Association for Research in Vision and Ophthalmology Annual Meeting, May 2021.
3. Miller A., Yazici A., Petrincec E., Carbone M., Miller C., Malik E., McCrossin C., Miller D., Analysis of Urgent Follow Up Visits and Complications After Intravitreal Injections: A Retrospective Cohort Study. Association for Research in Vision and Ophthalmology Annual Meeting, May 2021.

4. Obri M., Miller A., Miller D., Analysis of after-hours emergent ophthalmic surgery in the ambulatory surgery center setting. Association for Research in Vision and Ophthalmology Annual Meeting, May 2020.
5. Miller A., Obri M., Miller D. Preoperative telephone medical clearance for ophthalmic surgeries. Association for Research in Vision and Ophthalmology Annual Meeting, May 2020.
6. Miller D., Miller C., Wuller A., Platt S., Schartman J., Lewis S., Rowland D., Rao L. Frequency and symptoms of intravitreal silicone oil droplets following bevacizumab injections from BD insulin syringes. Association for Research in Vision and Ophthalmology Annual Meeting, May 2020.
7. Malik E., Wilneff M., Petrincec E., Platt S., Novak M., Miller D. Unexpected poor visual acuity outcomes follow silicone oil tamponade of retinal detachments. Association for Research in Vision and Ophthalmology Annual Meeting, May 2020.
8. Brown CC, Miller DG. Results of surgical management of senile macular holes by 25-gauge trans-conjunctival sutureless vitrectomy. *American Society of Retina Specialists Meeting Abstracts*; 2006; <http://www.asrs.org/meetings/abstracts/2006/>.
9. Federman JL, Martidis A, Nelson ML, Belmont JB, Sivalingam A, Miller DG. Intravitreal triamcinolone for refractory diabetic macular edema. *Macula Society Meeting Abstracts*, 2002, p 32.
10. Nelson ML, Martidis A, Miller DG, Spinak DJ, Federman JL. Intravitreal triamcinolone acetone injection for refractory pseudophakic cystoid macular edema. *Retina Congress 2002 Abstracts*, <http://www.vitreoussociety.org/sf2002/index.html>
11. Blade KA, Martidis A, Nelson ML, Belmont JB, Miller DG, Ansari I, Sivalingam A. Intravitreal triamcinolone injection for the treatment of macular edema secondary to branch retinal vein occlusion. *Retina Congress 2002 Abstracts*, <http://www.vitreoussociety.org/sf2002/index.html>
12. Martidis A, Nelson ML, Baker B, Duker JS, Reichel E, Rogers AH, Federman JL, Sivalingam A, Belmont JB, Miller DG. Intravitreal triamcinolone for refractory diabetic macular edema. *Retina Congress 2002 Abstracts*, <http://www.vitreoussociety.org/sf2002/index.html>

Posters

1. Yalamanchili S, Rao L, Rowland D, Gonzalez C, Miller D, Novak M, Pendergast S, Coney J, Schartman J, Lewis S. Comparative Success of Retinal detachment Repair among Private Practice Surgeons. The American Society of Retina Specialists, July 2019.

2. Miller D, Chandra R, Fill L, Miller C, Gan J, Giltner A, Pendergast S. Neovascular glaucoma presenting characteristics in a referral-based setting. Scientific Poster A0526. Association for Research in Vision and Ophthalmology Annual Meeting, April-May 2019.
3. Daroszewski D, Coney J, Schartman J, Miller D, Rao L, Zegarra H. Efficacy of the 0.19 mg fluocinolone acetonide (FAc) 4 (iluvien®) in a multiphysician, single-practice setting – the Cleveland experience. Poster B0155, Association for Research in Vision and Ophthalmology Annual Meeting, April-May 2019.
4. Sciulli H, Miller A, Obri M, Miller C, Hornik J, Miller D. Comparison of patient volumes between academic and private practice retinal specialists. Scientific Poster B0384, Association for Research in Vision and Ophthalmology Annual Meeting, April-May 2019.
5. Miller C, Miller A, Obri M, Hornik J, Rowland D, Miller D. Correlation of Medicare patient volume and online ratings for retinal physicians. Scientific Poster B0392, Association for Research in Vision and Ophthalmology Annual Meeting, April-May 2019.
6. Chandra C, Pophal C, Miller A, Hornik J, Schartman J, Coney J, Singerman L, David D. Efficacy of macular hole surgery in patients with idiopathic macular telangiectasia Type 2. Scientific Poster A0222, Association for Research in Vision and Ophthalmology Annual Meeting, April-May 2019.
7. Pophal C, Chandra R, Hornik J, Miller D, Singerman L, Zegarra H, Novak M, Pendergast S, Coney J, Rao L, Zakov ZN, Schartman J. Surgical outcomes and patient satisfaction in vitrectomy for vitreous floaters. Scientific Poster A0228, Association for Research in Vision and Ophthalmology Annual Meeting, April-May 2019.
8. Liu J, Coney J, Schartman J, Miller DG, Zegarra H, Rao L. Fluocinolone acetonide (FAc) 0.2 mg intravitreal implant in the treatment of diabetic macular edema (DME). Scientific Poster 4816 - C0174, Association for Research in Vision and Ophthalmology Annual Meeting, May 2018.
9. Abdelaziz M, Rostamizadeh M, Miller DG. The use of anti-VEGF in proliferative macular telangiectasia type 2. Scientific Poster 2145/ C0052, Association for Research in Vision and Ophthalmology Annual Meeting, May 2016.
10. Rostamizadeh M, Abdelaziz M, Patel A, Moarefi M, Miller D, Coney J, Novak M, Rao L, Pendergast S, Singerman L. Incidence of endophthalmitis in various anti-VEGF treatments. Scientific Poster 5025/ B0231, Association for Research in Vision and Ophthalmology Annual Meeting, May 2016.
11. Miller AG, Rao L, Rowland DY, Hornik J. The effect of requiring patient-specific prescriptions on the utilization of intravitreal bevacizumab. Scientific Poster 5584/A0193, Association for Research in Vision and Ophthalmology Annual Meeting, May 2014.

12. Sciulli H, Miller DG, Coney JM, Novak MA, Schartman JP, Singerman LJ, Zegarra H. Efficacy of ranibizumab in the treatment of diabetic macular edema refractory to bevacizumab. Scientific Poster 2409/ C0110, Association for Research in Vision and Ophthalmology Annual Meeting, May 2013.
13. Miller DG, Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy worsening (progression) at 1 year and 3 years in a randomized clinical trial evaluating ranibizumab and triamcinolone. Scientific Poster 366/D917, Association for Research in Vision and Ophthalmology Annual Meeting, May 2012.
14. Brown CC, Miller DG. Results of surgical management of senile macular holes by 25-gauge trans-conjunctival sutureless vitrectomy. Scientific Poster 4641/B976, Association for Research in Vision and Ophthalmology Annual Meeting, May 2006.
15. Prenner JL, Thompson JT, Miller DG, Saran BR, Gordon JF, Brucker AJ, Reich SJ. An open label study for the evaluation of tolerability of five dose levels of intravitreal VEGF siRNA (Cand5) in patients with wet age-related macular degeneration. Scientific Poster 4632, American Academy of Ophthalmology Annual Meeting, October 2005.
16. Sharma MC, Miller DG, Zakov ZN, Pendergast SD, Novak MA, Zegarra H, Singerman LJ. Results of the surgical management of idiopathic epiretinal membrane. Scientific Poster 472, American Academy of Ophthalmology Annual Meeting, October 2005.
17. Spinak DJ, Martidis A, Miller DG. Intravitreal triamcinolone acetonide injection for refractory pseudophakic cystoid macular edema. Scientific Poster 129, American Academy of Ophthalmology Annual Meeting, October 2002.